Trial Profile
Biomarker study for afatinib plus bevacizimab
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 May 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 10 May 2021 Status changed from recruiting to active, no longer recruiting.
- 08 May 2018 New trial record